Vipera aspis venom reduces lethality and down-regulates tumor necrosis factor-α in a rat model of LPS-induced sepsis

Cytokine

Volumn 49, Issue 3, 2010, Pages 319-324

  Frolkis, Inna ^a   Klein, Yifat ^a   Locker, Chaim ^a   Adi, Nimrod ^a   Dahan, Esther ^a   Uretzsky, Gideon ^a   Shapira, Itzhak ^a   Sorkine, Patrick ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Septic shock; TNF ; Vipera aspis venom (VAV)

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 10; INTERLEUKIN 6; LACTATE DEHYDROGENASE; SNAKE VENOM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ESCHERICHIA COLI; IMMUNOMODULATION; LETHALITY; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RAT; SEPTIC SHOCK; SNAKE; SURVIVAL RATE; THROMBOCYTE COUNT; VIPERA ASPIS; WISTAR RAT;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; LIPOPOLYSACCHARIDES; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SHOCK, SEPTIC; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; VIPER VENOMS; VIPERIDAE;

MAMMALIA; RATTUS; RATTUS NORVEGICUS; VIPERA ASPIS;

EID: 75449101576     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.11.019     Document Type: Article

References (58)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001) 1303-1310
2. Dombrovskiy V.Y., Martin A.A., Sunderram J., and Paz H.L. Facing the challenge: decreasing case fatality rates in severe sepsis despite increasing hospitalizations. Crit Care Med 33 (2005) 2555-2562
3. Dombrovskiy V.Y., Martin A.A., Sunderram J., and Paz H.L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35 (2007) 1244-1250
4. Esper A., and Martin G.S. Is severe sepsis increasing in incidence AND severity?. Crit Care Med 35 (2007) 1414-1415
5. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
6. Padkin A., Goldfrad C., Brady A.R., Young D., Black N., and Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 31 (2003) 2332-2338
7. Vincent J.L., Sakr Y., Sprung C.L., Ranieri V.M., Reinhart K., Gerlach H., et al. Sepsis Occurrence in Acutely Ill Patients I. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34 (2006) 344-353
8. Lamping N., Dettmer R., Schroder N.W., Pfeil D., Hallatschek W., Burger R., et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 101 (1998) 2065-2071
9. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Kahn R.J., and Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103 (1993) 565-575
10. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., et al. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470-474
11. Galanos C., Freudenberg M.A., Luderitz O., Rietschel E.T., and Westphal O. Chemical, physicochemical and biological properties of bacterial lipopolysaccharides. Prog Clin Biol Res 29 (1979) 321-332
12. Loppnow H., Libby P., Freudenberg M., Krauss J.H., Weckesser J., and Mayer H. Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatus LPS. Infect Immun 58 (1990) 3743-3750
13. Movat H.Z., Cybulsky M.I., Colditz I.G., Chan M.K., and Dinarello C.A. Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. Fed Proc 46 (1987) 97-104
14. Ziegler E.J., McCutchan J.A., Fierer J., Glauser M.P., Sadoff J.C., Douglas H., et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307 (1982) 1225-1230
15. Beutler B., Milsark I.W., and Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229 (1985) 869-871
16. Colletti L.M., Kunkel S.L., Walz A., Burdick M.D., Kunkel R.G., Wilke C.A., et al. The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 23 (1996) 506-514
17. Dominguez Fernandez E., Flohe S., Siemers F., Nau M., and Schade F.U. Endotoxin tolerance in rats: influence on LPS-induced changes in excretory liver function. Inflamm Res 51 (2002) 500-505
18. Chen R., Zhou H., Beltran J., Malellari L., and Chang S.L. Differential expression of cytokines in the brain and serum during endotoxin tolerance. J Neuroimmunol 163 (2005) 53-72
19. Szold O., Ben-Abraham R., Frolkis I., Sorkine M., and Sorkine P. Tumor necrosis factor as a mediator of cardiac toxicity following snake envenomation. Crit Care Med 31 (2003) 1449-1453
20. Szold O., Ben-Abraham R., Weinbroum A.A., Englender T.E., Ovadia D., Sorkine M., et al. Antagonization of TNF attenuates systemic hemodynamic manifestations of envenomation in a rat model of Vipera aspis snakebite. Intensive Care Med 27 (2001) 884-888
21. de Haro L., Robbe-Vincent A., Saliou B., Valli M., Bon C., and Choumet V. Unusual neurotoxic envenomations by Vipera aspis aspis snakes in France. Hum Exp Toxicol 21 (2002) 137-145
22. Minnich D.J., and Moldawer L.L. Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis: progress and pitfalls. Proc Nutr Soc 63 (2004) 437-441
23. Bhattacharjee A.K., Opal S.M., Taylor R., Naso R., Semenuk M., Zollinger W.D., et al. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J Infect Dis 173 (1996) 1157-1163
24. Cross A.S., Opal S.M., Palardy J.E., Drabick J.J., Warren H.S., Huber C., et al. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21 (2003) 4576-4587
25. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 (1992) 864-874
26. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 26 Suppl. 1 (2000) S64-74
27. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., and Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 (1995) 117-123
28. Schoenberg M.H., Weiss M., and Radermacher P. Outcome of patients with sepsis and septic shock after ICU treatment. Langenbecks Arch Surg 383 (1998) 44-48
29. Dinarello C.A., Gelfand J.A., and Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269 (1993) 1829-1835
30. Aderka D., Engelmann H., Wysenbeek A.J., and Levo Y. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr J Med Sci 28 (1992) 126-130
31. Bemelmans M.H., van Tits L.J., and Buurman W.A. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 16 (1996) 1-11
32. Cavaillon J.M., Fitting C., and Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 20 (1990) 253-257
33. Old L.J. Tumor necrosis factor (TNF). Science 230 (1985) 630-632
34. Beutler B., and Cerami A. The biology of cachectin/TNF-α primary mediator of the host response. Annu Rev Immunol 7 (1989) 625-655
35. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
36. Damas P., Canivet J.L., de Groote D., Vrindts Y., Albert A., Franchimont P., et al. Sepsis and serum cytokine concentrations. Crit Care Med 25 (1997) 405-412
37. Lin W.J., and Yeh W.C. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 24 (2005) 206-209
38. van der Poll T., and Lowry S.F. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?. Shock 3 (1995) 1-12
39. Abraham E., Anzueto A., Gutierrez G., Tessler S., San Pedro G., Wunderink R., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351 (1998) 929-933
40. Abraham E., Glauser M.P., Butler T., Garbino J., Gelmont D., Laterre P.F., et al. P55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277 (1997) 1531-1538
41. Abraham E., Wunderink R., Silverman H., Perl T.M., Nasraway S., Levy H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273 (1995) 934-941
42. Cohen J., and Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International sepsis trial study group. Crit Care Med 24 (1996) 1431-1440
43. Fisher Jr. C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334 (1996) 1697-1702
44. Fisher Jr. C.J., Opal S.M., Dhainaut J.F., Stephens S., Zimmerman J.L., Nightingale P., et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 21 (1993) 318-327
45. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151 (1993) 1548-1561
46. Bone R.C. The pathogenesis of sepsis. Ann Intern Med 115 (1991) 457-469
47. Bone R.C. Immunologic dissonance. a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125 (1996) 680-687
48. Le J., and Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 56 (1987) 234-248
49. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318 (1988) 1481-1486
50. Ramadori G., Van Damme J., and Rieder H. Meyer zum Buschenfelde KH. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 18 (1988) 1259-1264
51. Tabor D.R., Burchett S.K., and Jacobs R.F. Enhanced production of monokines by canine alveolar macrophages in response to endotoxin-induced shock. Proc Soc Exp Biol Med 187 (1988) 408-415
52. Gogos C.A., Drosou E., Bassaris H.P., and Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181 (2000) 176-180
53. van Deuren M., van der Ven-Jongekrijg J., Bartelink A.K., van Dalen R., Sauerwein R.W., and van der Meer J.W. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 172 (1995) 433-439
54. Moon D.O., Park S.Y., Lee K.J., Heo M.S., Kim K.C., Kim M.O., et al. Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol 7 (2007) 1092-1101
55. Nam K.W., Je K.H., Lee J.H., Han H.J., Lee H.J., Kang S.K., et al. Inhibition of COX-2 activity and proinflammatory cytokines (TNF-alpha and IL-1beta) production by water-soluble sub-fractionated parts from bee (Apis mellifera) venom. Arch Pharm Res 26 (2003) 383-388
56. Park H.J., Lee S.H., Son D.J., Oh K.W., Kim K.H., Song H.S., et al. Antiarthritic effect of bee venom: inhibition of inflammation mediator generation by suppression of NF-κB through interaction with the p50 subunit. Arthritis Rheum 50 (2004) 3504-3515
57. Opal S.M., and Cross A.S. The use of immunocompromised animals as models for human septic shock. Shock 24 Suppl. 1 (2005) 64-70
58. Grau G.E., and Maennel D.N. TNF inhibition and sepsis-sounding a cautionary note. Nat Med 3 (1997) 1193-1195